Aligos Therapeutics, Inc. (ALGS) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-94.17M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.24× | Operating cash flow / net income. Period ending 2026-06-30. $-94.17M ÷ $-75.96M ≈ 1.24× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -94.17M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 3.74M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -75.96M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-94.17M | (m) | (m) | $3.74M | (m) | $-75.96M | (m) | (m) | (m) | 1.24× |
| 2026-03-31 | (m) | (m) | $-84.72M | (m) | (m) | $4.71M | (m) | $-90.32M | (m) | (m) | (m) | 0.94× |
| 2025-12-31 | (m) | (m) | $-82.50M | (m) | (m) | $2.19M | (m) | $-24.19M | (m) | (m) | (m) | 3.41× |
| 2025-09-30 | (m) | (m) | $-79.16M | (m) | (m) | $2.62M | (m) | $-86.46M | (m) | (m) | (m) | 0.92× |
| 2025-06-30 | (m) | (m) | $-74.92M | (m) | (m) | $3.13M | (m) | $-74.18M | (m) | (m) | (m) | 1.01× |
| 2025-03-31 | (m) | (m) | $-78.91M | (m) | (m) | $3.23M | (m) | $-53.26M | (m) | (m) | (m) | 1.48× |
| 2024-12-31 | $-80.87M | (m) | $-80.74M | $130.00K | (m) | $3.61M | (m) | $-131.21M | (m) | (m) | -2239.63% | 0.62× |
| 2024-09-30 | (m) | (m) | $-85.00M | (m) | (m) | $3.68M | (m) | $-76.95M | (m) | (m) | (m) | 1.10× |
| 2024-06-30 | (m) | (m) | $-85.23M | (m) | (m) | $3.51M | (m) | $-75.73M | (m) | (m) | (m) | 1.13× |
| 2024-03-31 | (m) | (m) | $-79.36M | (m) | (m) | $6.75M | (m) | $-99.59M | (m) | (m) | (m) | 0.80× |
| 2023-12-31 | $-79.02M | (m) | $-79.00M | $19.00K | (m) | $6.19M | (m) | $-87.68M | (m) | (m) | -1276.30% | 0.90× |
| 2023-09-30 | (m) | (m) | $-73.12M | (m) | (m) | $5.52M | (m) | $-81.67M | (m) | (m) | (m) | 0.90× |
| 2023-06-30 | (m) | (m) | $-69.92M | (m) | (m) | $4.43M | (m) | $-82.25M | (m) | (m) | (m) | 0.85× |
| 2023-03-31 | $-81.78M | (m) | $-81.34M | $435.00K | (m) | (m) | (m) | $-83.39M | (m) | (m) | (m) | 0.98× |
| 2022-12-31 | $-80.33M | (m) | $-79.39M | $943.00K | (m) | $0.00 | (m) | $-96.05M | (m) | (m) | (m) | 0.83× |
| 2022-09-30 | $-101.27M | (m) | $-100.09M | $1.19M | (m) | (m) | (m) | $-111.87M | (m) | (m) | (m) | 0.89× |
| 2022-06-30 | $-109.60M | (m) | $-108.32M | $1.28M | (m) | (m) | (m) | $-126.38M | (m) | (m) | (m) | 0.86× |
| 2022-03-31 | $-107.40M | (m) | $-106.30M | $1.10M | (m) | (m) | (m) | $-136.27M | (m) | (m) | (m) | 0.78× |
| 2021-12-31 | $-116.55M | (m) | $-115.66M | $892.00K | (m) | $0.00 | (m) | $-128.33M | (m) | (m) | (m) | 0.90× |
| 2021-09-30 | $-98.48M | (m) | $-97.87M | $617.00K | (m) | (m) | (m) | $-125.04M | (m) | (m) | (m) | 0.78× |
| 2021-06-30 | $-89.93M | (m) | $-89.06M | $864.00K | (m) | (m) | (m) | $-125.21M | (m) | (m) | (m) | 0.71× |
| 2021-03-31 | $-85.02M | (m) | $-83.74M | $1.28M | (m) | (m) | (m) | $-116.19M | (m) | (m) | (m) | 0.72× |
| 2020-12-31 | $-76.33M | (m) | $-74.26M | $2.06M | (m) | $0.00 | (m) | $-108.54M | (m) | (m) | (m) | 0.68× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-49.55M | (m) | $-46.77M | $2.79M | (m) | (m) | (m) | $-52.26M | (m) | (m) | (m) | 0.89× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |